

DR. MARCO BIANCHI

CURRICULUM VITAE ET STUDIORUM

Nato a Novara (Italia) il 24 Agosto 1983

Scuole Medie Superiori: (terminate con la valutazione di 94/100 in Luglio 2002)

Liceo Scientifico Antonelli

Novara

Laurea magistrale in Medicina e Chirurgia (terminata con la valutazione di 106/110 il 22/07/2008)

Titolo della tesi: “LA PROSTATECTOMIA RADICALE E’ CURATIVA IN PAZIENTI SELEZIONATI CON CARCINOMA DELLA PROSTATA N+. PROPOSTA DI UNA NUOVA CLASSIFICAZIONE E SVILUPPO DI UN MODELLO PREDITTIVO DI SOPRAVVIVENZA A LUNGO TERMINE”

Università Vita-Salute San Raffaele

Ospedale San Raffaele

Milano (Italia)

Ottobre 2004- Luglio 2005: Internato elettivo presso il Dipartimento di Chirurgia Generale, Università Vita-Salute San Raffaele, Ospedale San Raffaele.

Agosto 2005-Luglio 2008: Internato elettivo presso il Dipartimento di Urologia, Università Vita-Salute San Raffaele, Ospedale San Raffaele.

Ottobre 2008: superamento del corso di “Good Clinical Practice” per studi clinici randomizzati a Barcelona.

Luglio 2009-Luglio2014: Specializzando in Urologia presso il Dipartimento di Urologia, Università Vita-Salute San Raffaele, Ospedale San Raffaele, Milano.

Genanio 2011-Giugno 2012: Fellowship di ricerca clinica presso il “Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center” (Direttore Dr. P.I. Karakiewicz).

Settembre 2012-Marzo 2014: Responsabile degli specializzandi, Dipartimento di Urologia, Università Vita-Salute San Raffaele, Ospedale San Raffaele, Milano.

Diploma di specializzazione in Urologia presso Dipartimento di Urologia, Università Vita-Salute San Raffaele, Ospedale San Raffaele, Milano (valutazione di 70/70 e Lode il 08/07/2014).

Titolo della tesi: “LYMPH NODES IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: ONCOLOGICAL OUTCOMES OF PATIENTS WITH POSITIVE NODES AND PERIOPERATIVE OUTCOMES OF AN EXTENDED PELVIC LYMPHADENECTOMY WITH ROBOTIC ASSISTED APPROACH: RESULTS FROM A SINGLE TERTIARY CARE CENTER“

Università Vita-Salute San Raffaele

Ospedale San Raffaele

Milano (Italia)

Dottore di Ricerca (PhD) in Oncologia molecolare, traslazione e tecniche chirurgiche innovative da Febbraio 2018 con la tesi: “SINGLE NUCLEOTIDE POLYMORPHISMS AND RISK OF PROSTATE CANCER: DEVELOPMENT AND VALIDATION OF A NOVEL GENETIC RISK SCORE FOR INDIVIDUALIZED SCREENING AND DIAGNOSTIC PROGRAMMES”

Università degli studi Magna-Graecia,

Catanzaro

POSIZIONE ATTUALE

Urologo presso il Dipartimento di Urologia

Ospedale San Raffaele

Via Olgettina 60, 20132, Milano

MEMBRO DI SOCIETA' SCIENTIFICHE

- 2009 - oggi Società Italiana di Urologia (SIU; Italia)
- 2009 - oggi European Association of Urology (EAU; Europe)
- 2013 - oggi American Urological Association (AUA; USA)
- 2017 - oggi Società italiana di Andrologia (SIA)

REVISORE PER RIVISTE SCIENTIFICHE INTERNAZIONALI

- 2012- oggi European Urology
- 2012- oggi European Urology Supplements
- 2012- oggi British Journal of Urology
- 2012- oggi International Journal of Urology
- 2012- oggi Current Urology
- 2012- oggi Canadian Urological Association Journal
- 2012- oggi Annals of surgical Oncology
- 2014- oggi Annals of medicine and Surgery
- 2016- oggi Journal of Urology
- 2016- oggi Urology
- 2016- oggi Minerva Urologica e nefrologica
- 2016- oggi Urologic Oncology: Seminars and Original Investigations
- 2016- oggi Therapeutic Advances in Urology
- 2019- oggi European Urology Oncology

INVESTIGATORE IN STUDI CLINICI

Eli Lilly: H6D-MC-LVHX “A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subject with Erectile Dysfunction who are Naïve to PDE5 Inhibitors”

FE 200486 CS29 “An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy”

Eli Lilly: H6D-MC-LVHJ “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia”

TrueNTH Global Registry PCO-CRV (Prostate Cancer Outcome – Comparing and Reducing Variations) project.

PREMI E RICONOSCIMENTI

2014 - **Premio Cosciani Cunico** per la miglior tesi di specializzazione in urologia della Lombardia

2016 - **Best poster al congresso europeo di urologia** (EAU 2016 monaco): “Historical trends in high-risk prostate cancer patients Characteristics: a 27 years old observational study from the European multicenter prostate cancer clinical and translational Research group (EMPACT) data base”

INDICE DELLE PUBBLICAZIONI SU RIVISTE SCIENTIFICHE INTERNAZIONALI

PUBBLICAZIONI SCIENTIFICHE COMPLESSIVE SU RIVISTE "PEER-REVIEWED": 118
CITATION INDEX: 3860
H-INDEX: 33
FONTE: SCOPUS. DATA RICERCA: 03/12/2019

- 1. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.**
Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F
- 2. Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.**
Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M, Joniau TS, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).
Eur Urol Oncol. 2019 Jul;2(4):456-463.
- 3. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.**
Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F.
J Clin Oncol. 2018 Oct 20;JCO1801148.
- 4. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches.**
Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, Shariat SF, Montorsi F, Briganti A.
Urologia. 2017 Feb 3;84(1):9-19. doi: 10.5301/uro.5000139. Epub 2015 Dec 16. Review.
- 5. Metabolic syndrome in white European men presenting for primary couple's infertility: investigation of the clinical and reproductive burden.**
Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, Castagna G, Clementi MC, La Croce G, Regina C, Bianchi M, Mirone V, Damiano R, Montorsi F, Salonia A.
Andrology. 2016 Sep;4(5):944-51. doi: 10.1111/andr.12232. Epub 2016 Jul 1.
- 6. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.**
Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, Briganti A, Spahn M, Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R.
World J Urol. 2016 Oct;34(10):1367-72.
- 7. Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?**

Rossi MS, Moschini M, **Bianchi M**, Gandaglia G, Fossati N, Dell'Oglio P, Schiavina R, Brunocilla E, Farina E, Picozzi M, Salonia A, Montorsi F, Briganti A.
J Sex Med. 2016 Apr;13(4):669-78. doi: 10.1016/j.jsxm.2016.02.160. Epub 2016 Mar 25.

8. The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status.

Moschini M, **Bianchi M**, Gandaglia G, Cucchiara V, Luzzago S, Pellucchi F, Damiano R, Serretta V, Briganti A, Montorsi F, Salonia A, Colombo R.
Eur Urol Focus. 2016 Apr;2(1):86-91. doi: 10.1016/j.euf.2015.03.002. Epub 2015 Jun 3.

9. Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution.

Moschini M, **Bianchi M**, Rossi MS, Dell'Oglio P, Gandaglia G, Fossati N, Mattei A, Damiano R, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.
Urol Oncol. 2016 Jun;34(6):256.e7-256.e13. doi: 10.1016/j.urolonc.2015.12.016. Epub 2016 Feb 2.

10. Penile rehabilitation after radical prostatectomy: does it work?

Gandaglia G, Suardi N, Cucchiara V, **Bianchi M**, Shariat SF, Roupret M, Salonia A, Montorsi F, Briganti A.
Transl Androl Urol. 2015 Apr;4(2):110-23. doi: 10.3978/j.issn.2223-4683.2015.02.01. Review.

11. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, **Bianchi M**, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.
Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

12. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.

Dell'Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, **Bianchi M**, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).
Urol Oncol. 2016 May;34(5):234.e13-9. doi: 10.1016/j.urolonc.2015.11.018. Epub 2015 Dec 17.

13. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.

Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, **Bianchi M**, Sacco V, Briganti A, Montorsi F, Calandrino R, Di Muzio N, Cozzarini C.
Radiother Oncol. 2016 Jan;118(1):79-84. doi: 10.1016/j.radonc.2015.11.020. Epub 2015 Dec 15.

14. Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.

Moschini M, Karnes RJ, Suardi N, **Bianchi M**, Pellucchi F, Rocchini L, Damiano R, Serretta V, Salonia A, Montorsi F, Briganti A, Colombo R.
Clin Genitourin Cancer. 2016 Jun;14(3):e245-50. doi: 10.1016/j.clgc.2015.08.003. Epub 2015 Aug 18.

15. **Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy.**
Moschini M, Briganti A, Murphy CR, **Bianchi M**, Gandaglia G, Montorsi F, Quevedo JF, Carlson R, Kwon E, Karnes RJ.
Eur Urol. 2016 Feb;69(2):193-6. doi: 10.1016/j.eururo.2015.07.047. Epub 2015 Aug 8.
16. **A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.**
Gallina A, **Bianchi M**, Gandaglia G, Cucchiara V, Suardi N, Montorsi F, Briganti A.
Eur Urol. 2015 Nov;68(5):750-3. doi: 10.1016/j.eururo.2015.02.002. Epub 2015 Feb 17.
17. **Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy.**
Simone G, **Bianchi M**, Giannarelli D, Daneshmand S, Papalia R, Ferriero M, Guaglianone S, Sentinelli S, Colombo R, Montorsi F, Collura D, Muto G, Novara G, Hurle R, Rink M, Fisch M, Abol-Enein H, Miranda G, Desai M, Gill I, Gallucci M.
World J Urol. 2015 Oct;33(10):1419-28. doi: 10.1007/s00345-014-1465-4. Epub 2014 Dec 27.
18. **Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy.**
Gandaglia G, Gallina A, Suardi N, Abdollah F, Passoni N, **Bianchi M**, Zaffuto E, Nini A, Vizziello D, Salonia A, Montorsi F, Briganti A.
Int J Impot Res. 2014 Nov-Dec;26(6):201-4. doi: 10.1038/ijir.2014.10. Epub 2014 May 1. PMID: 24784890 [PubMed - in process]
19. **Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy.**
Simone G, **Bianchi M**, Giannarelli D, Daneshmand S, Papalia R, Ferriero M, Guaglianone S, Sentinelli S, Colombo R, Montorsi F, Collura D, Muto G, Novara G, Hurle R, Rink M, Fisch M, Abol-Enein H, Miranda G, Desai M, Gill I, Gallucci M.; World J Urol. 2014 Dec 27. [Epub ahead of print] PMID: 25542395 [PubMed - as supplied by publisher]
20. **A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.**
Gallina A, **Bianchi M**, Gandaglia G, Cucchiara V, Suardi N, Montorsi F, Briganti A.
Eur Urol. 2015 Feb 17. pii: S0302-2838(15)00077-9. doi: 10.1016/j.eururo.2015.02.002. [Epub ahead of print] PMID: 25700565 [PubMed - as supplied by publisher]
21. **Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy.**
Hansen J, Gandaglia G, **Bianchi M**, Sun M, Rink M, Tian Z, Meskawi M, Trinh QD, Shariat SF, Perrotte P, Chun FK, Graefen M, Karakiewicz PI.
Can Urol Assoc J. 2014 Jan;8(1-2):E75-80. doi: 10.5489/cuaj.749.
22. **Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample.**
Becker A, **Bianchi M**, Hansen J, Tian Z, Shariat SF, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M.
World J Urol. 2014 Feb 11. [Epub ahead of print] PMID: 24515596
23. **A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.**

Ismail S, Meskawi M, Hansen J, **Bianchi M**, Tian Z, Latour M, Graefen M, Montorsi F, Trinh QD, Perrotte P, Karakiewicz PI, Sun M.
Crit Rev Oncol Hematol. 2014 Apr;90(1):49-57. doi: 10.1016/j.critrevonc.2013.12.003. Epub 2013 Dec 12. Review. PMID: 24411587

24. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.

Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, **Bianchi M**, Boorjian SA, Sun M, Karakiewicz PI, Montorsi F, Briganti A
Eur Urol. 2014 Mar;65(3):554-62. doi: 10.1016/j.eururo.2013.09.025. Epub 2013 Sep 27. PMID: 04576

25. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.

Bianchi M, Gandaglia G, Trinh QD, Hansen J, Becker A, Abdollah F, Tian Z, Lughezzani G, Roghmann F, Briganti A, Montorsi F, Karakiewicz PI, Sun M.
Urol Oncol. 2013 Sep 17. doi:pil: S1078-1439(13)00259-7. 10.1016/j.urolonc.2013.06.010. [Epub ahead of print]

26. Percentage of High-Grade Tumor Volume does not Meaningfully Improve Prediction of Early Biochemical Recurrence after Radical Prostatectomy Compared to Gleason Score.

Hansen J, **Bianchi M**, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, Shariat SF, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK.
BJU Int. 2013 Aug 23. doi: 10.1111/bju.12424. [Epub ahead of print]

27. Survival after nephroureterectomy for upper tract urothelial carcinoma: A population-based competing-risks analysis.

Gandaglia G, **Bianchi M**, Trinh QD, Becker A, Larouche A, Abdollah F, Roghmann F, Tian Z, Shariat SF, Briganti A, Montorsi F, Karakiewicz PI, Sun M.
Int J Urol. 2013 Aug 29. doi: 10.1111/iju.12267. [Epub ahead of print]

28. Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection.

Abdollah F, Cozzarini C, Sun M, Suardi N, Gallina A, Passoni NM, **Bianchi M**, Tutolo M, Fossati N, Nini A, Dell'oglio P, Salonia A, Karakiewicz P, Montorsi F, Briganti A.
Radiother Oncol. 2013 Jun 30. doi:pil: S0167-8140(13)00270-3. 10.1016/j.radonc.2013.05.029. [Epub ahead of print]

29. Robot-assisted vs. laparoscopic partial nephrectomy: utilization rates and perioperative outcomes.

Sammon JD, Karakiewicz PI, Sun M, Ravi P, Ghani KR, Jeong W, **Bianchi M**, Hansen J, Perrotte P, Peabody JO, Rogers CG, Shariat SF, Menon M, Trinh QD.
Int Braz J Urol. 2013 May-Jun;39(3):377-86. doi: 10.1590/S1677-5538.IBJU.2013.03.11.

30. Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis.

Ravi P, **Bianchi M**, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.
BJU Int. 2013 Jun 13. doi: 10.1111/bju.12288. [Epub ahead of print]

- 31. Percentage of High-Grade Tumor Volume does not Meaningfully Improve Prediction of Early Biochemical Recurrence after Radical Prostatectomy Compared to Gleason Score.**
Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, Shariat SF, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK.
BJU Int. 2013 Aug 23. doi: 10.1111/bju.12424. [Epub ahead of print]
- 32. Partial and radical nephrectomy provide comparable long-term cancer control for T1b renal cell carcinoma.**
Meskawi M, Becker A, Bianchi M, Trinh QD, Roghmann F, Tian Z, Graefen M, Perrotte P, Karakiewicz PI, Sun M.
Int J Urol. 2013 Jul 2. doi: 10.1111/iju.12204. [Epub ahead of print]
- 33. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma**
Sun M, Shariat SF, Trinh QD, Meskawi M, Bianchi M, Hansen J, Abdollah F, Perrotte P, Karakiewicz PI.
Ther Adv Urol. 2013 Apr;5(2):121-8. doi: 10.1177/1756287212466128.
- 34. Rates of open versus laparoscopic and partial versus radical nephrectomy for T1a renal cell carcinoma: A population-based evaluation.**
Bianchi M, Becker A, Abdollah F, Trinh QD, Hansen J, Tian Z, Shariat SF, Perrotte P, Karakiewicz PI, Sun M.
Int J Urol. 2013 Feb 19. doi: 10.1111/iju.12110. [Epub ahead of print]
- 35. Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?**
Sun M, Ravi P, Karakiewicz PI, Sukumar S, Sammon J, Bianchi M, Shariat SF, Jeong W, Ghani KR, Hansen J, Friedman A, Perrotte P, Peabody JO, Menon M, Trinh QD.
Urol Oncol. 2013 Feb 9. doi:pii: S1078-1439(12)00344-4. 10.1016/j.urolonc.2012.09.012. [Epub ahead of print]
- 36. Reply to Georgios Papadopoulos, Georgios Stathouros and Konstantinos Doumas' Letter to the editor Re: Maxine Sun, Marco Bianchi, Jens Hansen, et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol 2012;62:696-703.**
Sun M, Bianchi M, Karakiewicz PI, Trinh QD.
Eur Urol. 2013 May;63(5):e65-6. doi: 10.1016/j.eururo.2013.01.022. Epub 2013 Jan 30. No abstract available.
- 37. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.**
Alasker A, Meskawi M, Sun M, Ismail S, Hanna N, Hansen J, Tian Z, Bianchi M, Perrotte P, Karakiewicz PI.
Cancer Treat Rev. 2013 Jun;39(4):388-401. doi: 10.1016/j.ctrv.2012.12.006. Epub 2013 Jan 12.
- 38. Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy.**
Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, Shariat SF, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Ann Surg Oncol. 2013 Jun;20(6):2096-102. doi: 10.1245/s10434-012-2806-4. Epub 2012 Dec 23.

- 39. Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach.**
 Sammon JD, Karakiewicz PI, Sun M, Sukumar S, Ravi P, Ghani KR, **Bianchi M**, Peabody JO, Shariat SF, Perrotte P, Hu JC, Menon M, Trinh QD.
 J Urol. 2013 Apr;189(4):1289-94. doi: 10.1016/j.juro.2012.10.028. Epub 2012 Oct 22.
- 40. Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy.**
 Sun M, **Bianchi M**, Hansen J, Trinh QD, Karakiewicz PI.
 J Clin Oncol. 2012 Nov 1;30(31):3901; author reply 3902. doi: 10.1200/JCO.2012.43.7376. Epub 2012 Sep 17. No abstract available.
- 41. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.**
 Hansen J, Rink M, **Bianchi M**, Kluth LA, Tian Z, Ahyai SA, Shariat SF, Briganti A, Steuber T, Fisch M, Graefen M, Karakiewicz PI, Chun FK.
 Prostate. 2013 Jan;73(2):211-8. doi: 10.1002/pros.22559. Epub 2012 Jul 20.
- 42. National trends and disparities in the use of minimally invasive adult pyeloplasty.**
 Sukumar S, Sun M, Karakiewicz PI, Friedman AA, Chun FK, Sammon J, Ghani KR, Ravi P, **Bianchi M**, Jeong W, Shariat SF, Hansen J, Peabody JO, Elder JS, Menon M, Trinh QD.
 J Urol. 2012 Sep;188(3):913-8. doi: 10.1016/j.juro.2012.05.013. Epub 2012 Jul 20.
- 43. Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy.**
 Hansen J, Sun M, **Bianchi M**, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, Shariat SF, Chun FK, Perrotte P, Graefen M, Karakiewicz PI.
 Urology. 2012 Aug;80(2):347-53. doi: 10.1016/j.urology.2012.04.043. Epub 2012 Jun 13.
- 44. Predicting the risk of lymph node invasion during radical prostatectomy using the European Association of Urology guideline nomogram: a validation study.**
 Schmitges J, Karakiewicz PI, Sun M, Abdollah F, Budäus L, Isbarn H, **Bianchi M**, Trinh QD, Schlomm T, Chun FK, Graefen M, Steuber T.
 Eur J Surg Oncol. 2012 Jul;38(7):624-9. doi: 10.1016/j.ejso.2012.04.005. Epub 2012 Apr 22.
- 45. Reply from authors re: Brant A. Inman. Open versus laparoscopic nephroureterectomy: Is there really a debate?**
 Hanna, N., Sun, M., Bianchi, M., Karakiewicz, P.I.
 Eur Urol 2012;61:722-3
- 46. Insights of modern pathology reports originating from prostate biopsy and radical prostatectomy specimens.**
 Sun M, **Bianchi M**, Hansen J, Karakiewicz PI.
 Eur Urol. 2012 Jul;62(1):40-1. doi: 10.1016/j.eururo.2012.03.042. Epub 2012 Mar 30. No abstract available.
- 47. Marital status: a gender-independent risk factor for poorer survival after radical cystectomy.**
 Sammon JD, Morgan M, Djahangirian O, Trinh QD, Sun M, Ghani KR, Jeong W, Jhaveri J, Ehlert M, Schmitges J, **Bianchi M**, Shariat SF, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
 BJU Int. 2012 Nov;110(9):1301-9. doi: 10.1111/j.1464-410X.2012.10993.x. Epub 2012 Mar 27.

- 48. Leapfrog volume thresholds and perioperative complications after radical prostatectomy.**
Trinh QD, Sun M, Sammon J, Tian Z, **Bianchi M**, Shariat SF, Jeong W, Ghani KR, Jeldres C, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Cancer. 2012 Oct 15;118(20):4991-8. doi: 10.1002/cncr.27486. Epub 2012 Mar 5.
- 49. Blood transfusions in radical prostatectomy: a contemporary population-based analysis.**
Schmitges J, Sun M, Abdollah F, Trinh QD, Jeldres C, Budäus L, **Bianchi M**, Hansen J, Schlomm T, Perrotte P, Graefen M, Karakiewicz PI.
Urology. 2012 Feb;79(2):332-8. doi: 10.1016/j.urology.2011.08.079.
- 50. Disparities in access to care at high-volume institutions for uro-oncologic procedures.**
Trinh QD, Sun M, Sammon J, **Bianchi M**, Sukumar S, Ghani KR, Jeong W, Dabaja A, Shariat SF, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Cancer. 2012 Sep 15;118(18):4421-6. doi: 10.1002/cncr.27440. Epub 2012 Feb 1.
- 51. Prospective randomized trial of barbed polyglyconate suture to facilitate vesico-urethral anastomosis during robot-assisted radical prostatectomy: time reduction and cost benefit.**
Zorn KC, Trinh QD, Jeldres C, Schmitges J, Widmer H, Lattouf JB, Sammon J, Liberman D, Sun M, **Bianchi M**, Karakiewicz PI, Denis R, Gautam G, El-Hakim A.
BJU Int. 2012 May;109(10):1526-32. doi: 10.1111/j.1464-410X.2011.10763.x. Epub 2012 Jan 5.
- 52. Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort.**
Trinh QD, Schmitges J, **Bianchi M**, Sun M, Shariat SF, Sammon J, Jeldres C, Zorn K, Sukumar S, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
BJU Int. 2012 Jul;110(2 Pt 2):E21-7. doi: 10.1111/j.1464-410X.2011.10701.x. Epub 2011 Nov 1.
- 53. Morbidity and mortality of radical prostatectomy differs by insurance status.**
Trinh QD, Schmitges J, Sun M, Sammon J, Shariat SF, Zorn K, Sukumar S, **Bianchi M**, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Cancer. 2012 Apr 1;118(7):1803-10. doi: 10.1002/cncr.26475. Epub 2011 Aug 25.
- 54. Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance.**
Abdollah F, Suardi N, Capitanio U, Gallina A, Sun M, Villa L, Scattoni V, **Bianchi M**, Tutolo M, Fossati N, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.
BJU Int. 2013 Jun 7. doi: 10.1111/bju.12152. [Epub ahead of print]
- 55. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time.**
Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M.
BJU Int. 2013 Jun;111(8):E283-9. doi: 10.1111/bju.12115.
- 56. Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre.**

Briganti A, **Bianchi M**, Sun M, Suardi N, Gallina A, Abdollah F, Bertini R, Colombo R, Girolamo VD, Salonia A, Scattoni V, Karakiewicz PI, Guazzoni G, Rigatti P, Montorsi F. *BJU Int.* 2013 Jun;111(8):1222-30. doi: 10.1111/j.1464-410X.2012.11464.x. Epub 2012 Nov 13.

57. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.

Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, **Bianchi M**, Sun M, Fossati N, Passoni NM, Fiorino C, Di Muzio N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A. *Eur Urol.* 2013 Jun;63(6):998-1008. doi: 10.1016/j.eururo.2012.10.036. Epub 2012 Oct 26.

58. An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis.

Bianchi M, Becker A, Trinh QD, Abdollah F, Tian Z, Shariat SF, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI, Sun M. *BJU Int.* 2013 Jun;111(8):1184-90. doi: 10.1111/bju.12084. Epub 2013 Apr 12.

59. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.

Abdollah F, Suardi N, Gallina A, **Bianchi M**, Tutolo M, Passoni N, Fossati N, Sun M, Dell'oglio P, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A. *Ann Oncol.* 2013 Jun;24(6):1459-66. doi: 10.1093/annonc/mdt120. Epub 2013 Mar 18.

60. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection.

Passoni NM, Abdollah F, Suardi N, Gallina A, **Bianchi M**, Tutolo M, Fossati N, Gandaglia G, Salonia A, Freschi M, Rigatti P, Montorsi F, Briganti A. *Urol Oncol.* 2013 Mar 12. doi:pii: S1078-1439(12)00355-9. 10.1016/j.urolonc.2012.10.009. [Epub ahead of print]

61. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data

Sun M, Trinh QD, **Bianchi M**, Hansen J, Abdollah F, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI. *BJU Int.* 2013 Mar 12. doi: 10.1111/j.1464-410X.2012.11693.x. [Epub ahead of print]

62. FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients.

Meskawi M, Sun M, Ismail S, **Bianchi M**, Hansen J, Tian Z, Hanna N, Trinh QD, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. *Mod Pathol.* 2013 Feb 1. doi: 10.1038/modpathol.2012.230. [Epub ahead of print]

63. A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy.

Abdollah F, Sun M, Suardi N, Gallina A, Tutolo M, Passoni N, **Bianchi M**, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, Briganti A. *BJU Int.* 2013 May;111(6):905-13. doi: 10.1111/j.1464-410X.2012.11560.x. Epub 2013 Jan 17.

64. Optimizing postoperative sexual function after radical prostatectomy.

Tutolo M, Briganti A, Suardi N, Gallina A, Abdollah F, Capitanio U, **Bianchi M**, Passoni N, Nini A, Fossati N, Rigatti P, Montorsi F.

- 65. Does partial nephrectomy at an academic institution result in better outcomes?**
Trinh QD, Schmitges J, Sun M, Sammon J, Shariat SF, Sukumar S, Zorn K, **Bianchi M**, Jeldres C, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
World J Urol. 2012 Aug;30(4):505-10. doi: 10.1007/s00345-011-0759-z. Epub 2011 Sep 9.
- 66. Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States.**
Trinh QD, Schmitges J, Sun M, Sukumar S, Sammon J, Shariat SF, Jeldres C, **Bianchi M**, Tian Z, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI.
Cancer. 2012 Apr 1;118(7):1894-900. doi: 10.1002/cncr.26527. Epub 2011 Sep 6.
- 67. Open radical prostatectomy in the elderly: a case for concern?**
Trinh QD, Schmitges J, Sun M, Shariat SF, Sukumar S, Tian Z, **Bianchi M**, Sammon J, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI.
BJU Int. 2012 May;109(9):1335-40. doi: 10.1111/j.1464-410X.2011.10554.x. Epub 2011 Sep 6.
- 68. The effect of insurance status on outcomes after partial nephrectomy.**
Abdo A, Trinh QD, Sun M, Schmitges J, **Bianchi M**, Sammon J, Shariat SF, Sukumar S, Zorn K, Jeldres C, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI.
Int Urol Nephrol. 2012 Apr;44(2):343-51. doi: 10.1007/s11255-011-0056-1. Epub 2011 Sep 6.
- 69. Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study.**
Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, Shariat SF, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI.
Can Urol Assoc J. 2012 Aug;6(4):245-50. doi: 10.5489/cuaj.12032.
- 70. Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis.**
Sun M, **Bianchi M**, Hansen J, Abdollah F, Trinh QD, Lughezzani G, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
Int J Urol. 2013 Apr;20(4):372-80. doi: 10.1111/j.1442-2042.2012.03170.x. Epub 2012 Oct 8.
- 71. The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.**
Villa L, Capitanio U, Briganti A, Abdollah F, Suardi N, Salonia A, Gallina A, Freschi M, Russo A, Castiglione F, **Bianchi M**, Rigatti P, Montorsi F, Scattoni V.
J Urol. 2013 Mar;189(3):854-9. doi: 10.1016/j.juro.2012.09.100. Epub 2012 Sep 25.
- 72. Clinical and diagnostic assessment for therapeutic decisions in prostate cancer.**
Passoni NM, Di Trapani E, Suardi N, Gallina A, Abdollah F, **Bianchi M**, Picchio M, Giovacchini G, Messa C, Rigatti P, Montorsi F, Briganti A.
Q J Nucl Med Mol Imaging. 2012 Aug;56(4):321-30. Review.
- 73. In-hospital mortality and failure to rescue after cytoreductive nephrectomy.**
Trinh QD, **Bianchi M**, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M.
Eur Urol. 2013 Jun;63(6):1107-14. doi: 10.1016/j.eururo.2012.08.069. Epub 2012 Sep 7.

- 74. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.**
 Briganti A, Spahn M, Joniau S, Gontero P, **Bianchi M**, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).
 Eur Urol. 2013 Apr;63(4):693-701. doi: 10.1016/j.eururo.2012.08.054. Epub 2012 Sep 5.
- 75. The effect of gender on nephrectomy perioperative outcomes: a national survey.**
 Sammon J, Trinh QD, Sun M, **Bianchi M**, Schmitges J, Shariat SF, Ghani KR, Sukumar S, Jeldres C, Briganti A, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.
 Can J Urol. 2012 Aug;19(4):6337-44.
- 76. Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy.**
 Gandaglia G, Suardi N, Gallina A, Abdollah F, Capitanio U, Salonia A, Colombo R, **Bianchi M**, Chun FK, Hansen J, Rigatti P, Montorsi F, Briganti A.
 J Sex Med. 2012 Aug;9(8):2187-94. doi: 10.1111/j.1743-6109.2012.02812.x. Epub 2012 Jun 27.
- 77. Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery.**
 Suardi N, Moschini M, Gallina A, Gandaglia G, Abdollah F, Capitanio U, **Bianchi M**, Tutolo M, Passoni N, Salonia A, Hedlund P, Rigatti P, Montorsi F, Briganti A.
 BJU Int. 2013 May;111(5):717-22. doi: 10.1111/j.1464-410X.2012.11315.x. Epub 2012 Jun 21.
- 78. National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer.**
 Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, **Bianchi M**, Tutolo M, Passoni N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A; National Comprehensive Cancer Network.
 J Urol. 2012 Aug;188(2):423-8. doi: 10.1016/j.juro.2012.03.129. Epub 2012 Jun 13.
- 79. Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer?**
 Sun M, Abdollah F, Hansen J, Trinh QD, **Bianchi M**, Tian Z, Briganti A, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
 J Sex Med. 2012 Nov;9(11):2961-9. doi: 10.1111/j.1743-6109.2012.02806.x. Epub 2012 Jun 6.
- 80. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.**
 Briganti A, Wiegel T, Joniau S, Cozzarini C, **Bianchi M**, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, Montorsi F, Van Poppel H.
 Eur Urol. 2012 Sep;62(3):472-87. doi: 10.1016/j.eururo.2012.04.056. Epub 2012 May 16.
- 81. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥ 75 years with multiple comorbidities.**
 Sun M, **Bianchi M**, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
 BJU Int. 2013 Jan;111(1):67-73. doi: 10.1111/j.1464-410X.2012.11254.x. Epub 2012 May 22.

- 82. Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification.**
Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, **Bianchi M**, Tutolo M, Fossati N, Castiglione F, Freschi M, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.
Urol Oncol. 2012 May 14. [Epub ahead of print]
- 83. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.**
Abdollah F, Sun M, Schmitges J, Thuret R, **Bianchi M**, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.
J Urol. 2012 Jul;188(1):73-83. doi: 10.1016/j.juro.2012.03.005. Epub 2012 May 12.
- 84. A review of integrated staging systems for renal cell carcinoma.**
Meskawi M, Sun M, Trinh QD, **Bianchi M**, Hansen J, Tian Z, Rink M, Ismail S, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Aug;62(2):303-14. doi: 10.1016/j.eururo.2012.04.049. Epub 2012 May 3. Review
- 85. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis.**
Sun M, **Bianchi M**, Hansen J, Trinh QD, Abdollah F, Tian Z, Sammon J, Shariat SF, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Oct;62(4):696-703. doi: 10.1016/j.eururo.2012.03.051. Epub 2012 Mar 31.
- 86. Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy.**
Schmitges J, Trinh QD, Sun M, Abdollah F, **Bianchi M**, Budäus L, Hansen J, Eichelberg C, Perrotte P, Shariat SF, Menon M, Montorsi F, Graefen M, Karakiewicz PI.
Urology. 2012 Apr;79(4):796-803. doi: 10.1016/j.urology.2011.11.061.
- 87. Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool.**
Briganti A, Capitanio U, Abdollah F, Gallina A, Suardi N, **Bianchi M**, Tutolo M, Salonia A, Freschi M, Rigatti P, Montorsi F.
Prostate. 2012 Apr;72(5):499-506.
- 88. Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses.**
Abdollah F, Sun M, Suardi N, Gallina A, **Bianchi M**, Tutolo M, Passoni N, Tian Z, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, Briganti A.
Eur Urol. 2012 Jul;62(1):42-52. doi: 10.1016/j.eururo.2012.02.057. Epub 2012 Mar 8.
- 89. Discharge patterns after radical cystectomy: contemporary trends in the United States.**
Bianchi M, Trinh QD, Sun M, Sammon J, Schmitges J, Shariat SF, Sukumar S, Ghani KR, Jeldres C, Perrotte P, Rogers CG, Briganti A, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.
J Urol. 2012 Apr;187(4):1206-9. doi: 10.1016/j.juro.2011.11.097. Epub 2012 Feb 14.
- 90. Treatment management of small renal masses in the 21st century: a paradigm shift.**
Sun M, Abdollah F, **Bianchi M**, Trinh QD, Jeldres C, Thuret R, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

- 91. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.**
Schmitges J, Trinh QD, Sun M, Hansen J, **Bianchi M**, Jeldres C, Perrotte P, Dahlem R, Shariat SF, Chun FK, Montorsi F, Menon M, Fisch M, Graefen M, Karakiewicz PI.
BJU Int. 2012 Sep;110(6 Pt B):E183-90. doi: 10.1111/j.1464-410X.2012.10936.x. Epub 2012 Feb 9.
- 92. Venous thromboembolism after radical prostatectomy: the effect of surgical caseload.**
Schmitges J, Trinh QD, Sun M, Abdollah F, **Bianchi M**, Budäus L, Salomon G, Schlomm T, Perrotte P, Shariat SF, Montorsi F, Menon M, Graefen M, Karakiewicz PI.
BJU Int. 2012 Sep;110(6):828-33. doi: 10.1111/j.1464-410X.2012.10941.x. Epub 2012 Feb 7.
- 93. Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated?**
Gallina A, Ferrari M, Suardi N, Capitanio U, Abdollah F, Tutolo M, **Bianchi M**, Saccà A, Salonia A, Rigatti P, Montorsi F, Briganti A.
J Sex Med. 2012 Mar;9(3):903-8. doi: 10.1111/j.1743-6109.2011.02622.x. Epub 2012 Jan 12.
- 94. Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series.**
Hanna N, Sun M, Trinh QD, Hansen J, **Bianchi M**, Montorsi F, Shariat SF, Graefen M, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Apr;61(4):715-21. doi: 10.1016/j.eururo.2011.12.026. Epub 2011 Dec 22.
- 95. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample.**
Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, **Bianchi M**, Jeong W, Shariat SF, Hansen J, Schmitges J, Jeldres C, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.
Eur Urol. 2012 Apr;61(4):679-85. doi: 10.1016/j.eururo.2011.12.027. Epub 2011 Dec 22.
- 96. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy.**
Sun M, Abdollah F, **Bianchi M**, Trinh QD, Shariat SF, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
Eur J Cancer. 2012 Jul;48(10):1503-11. doi: 10.1016/j.ejca.2011.11.024. Epub 2011 Dec 21.
- 97. Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy.**
Sun M, **Bianchi M**, Trinh QD, Abdollah F, Schmitges J, Jeldres C, Shariat SF, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
J Urol. 2012 Feb;187(2):405-10. doi: 10.1016/j.juro.2011.10.025. Epub 2011 Dec 15.
- 98. A non-cancer-related survival benefit is associated with partial nephrectomy.**
Sun M, Trinh QD, **Bianchi M**, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2012 Apr;61(4):725-31. doi: 10.1016/j.eururo.2011.11.047. Epub 2011 Dec 3.
- 99. The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy.**
Schmitges J, Trinh QD, **Bianchi M**, Sun M, Abdollah F, Ahyai SA, Jeldres C, Steuber T, Perrotte P, Shariat SF, Menon M, Montorsi F, Graefen M, Karakiewicz PI.

Int Urol Nephrol. 2012 Jun;44(3):799-806. doi: 10.1007/s11255-011-0103-y. Epub 2011 Dec 13.

- 100. Discharge patterns after radical prostatectomy in the United States of America.**
Trinh QD, Bianchi M, Sun M, Sammon J, Schmitges J, Shariat SF, Sukumar S, Jeldres C, Zorn K, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI.
Urol Oncol. 2011 Nov 17. [Epub ahead of print]
- 101. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.**
Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F.
Eur Urol. 2012 Jun;61(6):1132-8. doi: 10.1016/j.eururo.2011.11.008. Epub 2011 Nov 12.
- 102. Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series.**
Abdollah F, Cozzarini C, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Salonia A, La Macchia M, Di Muzio N, Rigatti P, Montorsi F, Briganti A.
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):624-9. doi: 10.1016/j.ijrobp.2011.06.2014. Epub 2011 Nov 16.
- 103. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.**
Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F.
Eur Urol. 2012 Mar;61(3):480-7. doi: 10.1016/j.eururo.2011.10.044. Epub 2011 Nov 7.
- 104. Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: a national series.**
Sun M, Abdollah F, Shariat SF, Schmitges J, Trinh QD, Tian Z, Jeldres C, Abdo A, Bianchi M, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI.
Eur J Surg Oncol. 2012 Jan;38(1):80-7. doi: 10.1016/j.ejso.2011.09.035. Epub 2011 Oct 13.
- 105. There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies.**
Briganti A, Tutolo M, Suardi N, Gallina A, Abdollah F, Capitanio U, Freschi M, Bianchi M, Salonia A, Colombo R, Rigatti P, Montorsi F.
Prostate. 2012 Jun 1;72(8):925-30. doi: 10.1002/pros.21497. Epub 2011 Sep 30.
- 106. Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.**
Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, Shariat SF, Zorn K, Pharand D, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
BJU Int. 2012 Jun;109(12):1807-12. doi: 10.1111/j.1464-410X.2011.10569.x. Epub 2011 Sep 27.
- 107. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.**
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI.
Ann Oncol. 2012 Apr;23(4):973-80. doi: 10.1093/annonc/mdr362. Epub 2011 Sep 2.

- 108. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis.**
Sun M, Abdollah F, **Bianchi M**, Trinh QD, Jeldres C, Tian Z, Shariat SF, Widmer H, Zorn K, Menon M, Montorsi F, Perrotte P, Karakiewicz PI.
Eur Urol. 2011 Dec;60(6):1152-9. doi: 10.1016/j.eururo.2011.07.064. Epub 2011 Aug 5.
- 109. A population-based analysis of temporal perioperative complication rates after minimally invasive radical prostatectomy.**
Schmitges J, Trinh QD, Abdollah F, Sun M, **Bianchi M**, Budäus L, Zorn K, Perotte P, Schlomm T, Haese A, Montorsi F, Menon M, Graefen M, Karakiewicz PI.
Eur Urol. 2011 Sep;60(3):564-71. doi: 10.1016/j.eururo.2011.06.036. Epub 2011 Jun 25.
- 110. Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum.**
Briganti A, Suardi N, Capogrosso P, Passoni N, Freschi M, di Trapani E, Gallina A, Capitanio U, Abdollah F, Tutolo M, **Bianchi M**, Salonia A, Da Pozzo LF, Montorsi F, Rigatti P.
Prostate. 2012 Feb 1;72(2):186-92. doi: 10.1002/pros.21420. Epub 2011 May 2.
- 111. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.**
Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, **Bianchi M**, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M.
Eur Urol. 2011 May;59(5):832-40. doi: 10.1016/j.eururo.2011.02.024. Epub 2011 Feb 22.
- 112. What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy?**
Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, **Bianchi M**, Salonia A, Colombo R, Di Girolamo V, Martinez-Salamanca JI, Guazzoni G, Rigatti P, Montorsi F.
J Sex Med. 2011 Apr;8(4):1210-7. doi: 10.1111/j.1743-6109.2010.02179.x. Epub 2011 Jan 26.
- 113. Radical prostatectomy at academic versus nonacademic institutions: a population based analysis.**
Trinh QD, Schmitges J, Sun M, Shariat SF, Sukumar S, **Bianchi M**, Tian Z, Jeldres C, Sammon J, Perrotte P, Graefen M, Peabody JO, Menon M, Karakiewicz PI.
J Urol. 2011 Nov;186(5):1849-54. doi: 10.1016/j.juro.2011.06.068. Epub 2011 Sep 25.
- 114. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification.**
Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, **Bianchi M**, Passoni N, Salonia A, Colombo R, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F.
J Sex Med. 2010 Jul;7(7):2521-31. doi: 10.1111/j.1743-6109.2010.01845.x. Epub 2010 May 4.
- 115. Benign Prostatic Hyperplasia and Its Aetiologies**
Briganti, A., Capitanio, U., Suardi, N., Gallina, A., Salonia, A., Bianchi, M., Tutolo, M., Di Girolamo, V., Guazzoni, G., Rigatti, P., Montorsi, F.
European Urology Supplements,2009; 8(13), pp. 865-871
- 116. Prediction of sexual function after radical prostatectomy.**
Briganti A, Capitanio U, Chun FK, Karakiewicz PI, Salonia A, **Bianchi M**, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Cancer. 2009 Jul 1;115(13 Suppl):3150-9. doi: 10.1002/cncr.24349. Review.

117. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.

Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, **Bianchi M**, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P.

Eur Urol. 2009 May;55(5):1003-11. doi: 10.1016/j.eururo.2009.01.046. Epub 2009 Feb 4.

118. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.

Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, **Bianchi M**, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML.

Eur Urol. 2009 Feb;55(2):261-70. doi: 10.1016/j.eururo.2008.09.043. Epub 2008 Oct 1.